Novartis' Kisqali cuts recurrence risk in early-stage breast cancer

Novartis' Kisqali cuts recurrence risk in early-stage breast cancer

Source: 
BioSpace
snippet: 

Topline data from the Phase III NATALEE study showed Novartis’ Kisqali (ribociclib) met its primary endpoint, reducing the risk of recurrence in early breast cancer, the company announced Monday.